logo
Share SHARE
FONT-SIZE Plus   Neg

Telik Says FDA Grants Orphan Drug Status To Telintra, Shares Soar - Quick Facts

Telik, Inc. (TELK) announced that its product candidate, ezatiostat HCL (Telintra), has been granted orphan drug designation by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS).

Orphan designation grants potential US market exclusivity to a drug for the treatment of a specified condition for a period of seven years following FDA marketing approval.

Telintra is a novel inhibitor of the enzyme glutathione S-transferase P1-1, leading to activation of Jun kinase, a key regulator of cellular growth and differentiation of blood precursor cells.

Telintra has been shown to cause clinically significant and sustained reduction in red blood cell transfusions, transfusion independence and multilineage responses in MDS patients. The results of four clinical trials of Telintra in MDS have been reported in peer-reviewed scientific journals.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Canada based Maple Leaf Foods Inc. Wednesday said it has reached a definitive agreement with Brynwood Partner VI L.P. for the acquisition of Lightlife Foods Inc. The deal would be worth $140 million plus other costs. Light is a brand in U.S. for refrigerated plant based protein foods. A hedge fund is an alternative investment fund that uses pooled funds from accredited individuals or institutional investors and invests these funds in different assets with a goal of generating high returns. Hedge funds are generally accessible only to accredited or qualified investors. They cannot... Off-price retailer TJX Companies, Inc. reported a nearly 2 percent increase in profit for the fourth quarter from last year, reflecting higher sales and customer traffic. Both revenue and earnings per share for the quarter beat analysts' expectations. The company forecast earnings for the first quarter below the Street estimates and projects fiscal 2018 earnings above their expectations.
comments powered by Disqus
Follow RTT